Clinical response to rituximab by FCGR3A-158V/F polymorphism
| . | FCGR3A-158VV . | FCGR3A-158F carriers . | P* . |
|---|---|---|---|
| Clinical response at M2 | |||
| Objective response (%) | 10 (100) | 26 (67) | .03 |
| CR | 3 | 7 | |
| CRu | 1 | 2 | |
| PR | 6 | 17 | |
| No response (%) | 0 (0) | 13 (33) | |
| No change | 0 | 10 | |
| Progressive disease | 0 | 3 | |
| Clinical response at M12 | |||
| Objective response (%) | 9 (90) | 20 (51) | .03 |
| CR | 6 | 11 | |
| CRu | 1 | 2 | |
| PR | 2 | 7 | |
| No response (%) | 1 (10) | 19 (49) | |
| No change | 0 | 2 | |
| Progressive disease | 1 | 17 |
| . | FCGR3A-158VV . | FCGR3A-158F carriers . | P* . |
|---|---|---|---|
| Clinical response at M2 | |||
| Objective response (%) | 10 (100) | 26 (67) | .03 |
| CR | 3 | 7 | |
| CRu | 1 | 2 | |
| PR | 6 | 17 | |
| No response (%) | 0 (0) | 13 (33) | |
| No change | 0 | 10 | |
| Progressive disease | 0 | 3 | |
| Clinical response at M12 | |||
| Objective response (%) | 9 (90) | 20 (51) | .03 |
| CR | 6 | 11 | |
| CRu | 1 | 2 | |
| PR | 2 | 7 | |
| No response (%) | 1 (10) | 19 (49) | |
| No change | 0 | 2 | |
| Progressive disease | 1 | 17 |
Statistical comparison of homozygousFCGR3A-158V patients versus FCGR3A-158F carriers. Data concerning the 3 genotype subgroups are given in the text.